The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TRITON: Phase 3b study of tremelimumab (T) + durvalumab (D) vs pembrolizumab (P), in combination with chemotherapy (CT), in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11and/or KEAP1 and/or KRAS mutations.
 
Ferdinandos Skoulidis
Honoraria - CURIO, LLC; DAVA Oncology; Ideology Health; Intellisphere, LLC; Medscape; MI and T; MJH Life Sciences; PER
Consulting or Advisory Role - AImmune (I); Amgen; AstraZeneca; BergenBio; BridgeBio; Guardant Health; Hookipa Pharma; Merck Sharp & Dohme; Novartis; Novocure; Revolution Medicines; Tango Therapeutics
Research Funding - Amgen; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Pfizer; Revolution Medicines
Travel, Accommodations, Expenses - Amgen; AstraZeneca; DAVA Oncology; Ideology Health; Merck Sharp & Dohme; MI and T; PER; Revolution Medicines
 
Hossein Borghaei
Stock and Other Ownership Interests - Nucleai; Rgenix; Sonnet
Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Pfizer; Regeneron
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Bayer; Beigene; BerGenBio; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech; Genmab; Guardant Health; IO Biotech; ITeos Therapeutics; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; natera; Novartis; oncocyte; Pfizer; PharmaMar; Puma Biotechnology; Regeneron; Rgenix; Sonnet; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; EMD Serono; Genentech; Lilly; Merck; Novartis; Regeneron
Other Relationship - Incyte; Novartis; SpringWorks Therapeutics; Takeda; University of Pennsylvania
 
Edward B. Garon
Consulting or Advisory Role - ABBVIE/ABBOTT; Arcus Biosciences; AstraZeneca; Atreca; BridgeBio Pharma; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Hookipa Biotech; LianBio; Lilly; Merus; Novartis; Nuvalent, Inc.; Regeneron; Sanofi; Seagan; Sensei Biotherapeutics; Sumitomo Pharma Oncology; Summit Therapeutics; Synthekine; Zymeworks
Research Funding - ABL Bio (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Synthekine (Inst)
Patents, Royalties, Other Intellectual Property - Diagnosistic and therapeutic use of "Motif Neoepitopes" as defined by Cummings et al in Nature Cancer. (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics; Novartis
Other Relationship - Daiichi Sankyo/Astra Zeneca
 
Ticiana Leal
Consulting or Advisory Role - Abbvie; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; BMS GmbH & Co. KG; Catalyst Pharmaceuticals; Catalyst Pharmaceuticals; Genentech; Janssen; Jazz Pharmaceuticals; Novartis; Novocure; Novocure; Novocure; Novocure; OncoC4; Pfizer; Regeneron; Regeneron; Roche; Sanofi; Takeda; Takeda
Research Funding - Daiichi Sankyo/Astra Zeneca (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Regeneron; Sanofi
 
Stephen V. Liu
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Candel Therapeutics; Catalyst Pharmaceuticals; Daiichi Sankyo/UCB Japan; Elevation Oncology; Genentech; Gilead Sciences; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Merus; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; RAPT Therapeutics; Regeneron; Revolution Medicines; Sanofi; Takeda
Research Funding - Abbvie (Inst); Alkermes (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
 
Eric S. Nadler
Consulting or Advisory Role - AstraZeneca; Merck; Mirati Therapeutics; Novocure
Speakers' Bureau - AstraZeneca; Lilly; Mirati Therapeutics; Regeneron
 
Sandip Pravin Patel
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Certis Oncology Solutions; Compugen; Illumina; Iovance Biotherapeutics (Inst); Lilly; Lilly; Merck; Nektar; Novartis; Pfizer; Roche/Genentech; Tempus
Speakers' Bureau - Boehringer Ingelheim; Merck
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics; Takeda (Inst); Takeda (Inst)
 
Vamsidhar Velcheti
Honoraria - Galvanize Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Novocure; Picture Health; Regeneron; Taiho Oncology; Takeda
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); RSIP Vision (Inst); Trovagene (Inst)
 
Ashish Gautam
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; Exact Sciences
 
Ugochinyere Emeribe
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Luisa Luciani-Silverman
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb/Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Sanofi
 
John Heymach
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - AstraZeneca; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; DAVA Pharmaceuticals; EMD Serono; Genentech/Roche; GlaxoSmithKline; Hengrui Pharmaceutical; Janssen; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Lilly (Inst); Mirati Therapeutics; Nexus Health Systems; Pneuma Respiratory; Regeneron; Sanofi/Aventis; Spectrum Pharmaceuticals; Takeda
Speakers' Bureau - DAVA Pharmaceuticals; IDEOlogy Health; MJH Life Sciences
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Mirati Therapeutics; Spectrum Pharmaceuticals; Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations